UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2019

 

or

 

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT

 

For the transition period from N/A to N/A

 

Commission File No. 000-28745

 

Cipherloc Corporation

(Name of small business issuer as specified in its charter)

 

Texas   86-0837077
(State or other jurisdiction of   (IRS Employer
incorporation or organization)   Identification No.)

 

825 Main St, Suite 100

Buda, TX 78610

(Address of principal executive offices)

 

(512) 772-4237

Registrant’s telephone number, including area code

 

Indicate by check mark whether the Registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days:

Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer [  ] Accelerated filer [  ]
Non–Accelerated filer [  ] Smaller reporting company [X]
Emerging growth company [  ]    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b–2 of the Exchange Act).

Yes [  ] No [X]

 

Securities registered pursuant to Section 12(b) of the Act:

 

Class   Trading Symbol   Name of each exchange
on which registered
Common stock, $0.01 par value   CLOK   OTCQB Venture Market

 

As of May 30, 2019, 40,792,510 shares of the issuer’s common stock were outstanding.

 

 

 

     
     

 

CIPHERLOC CORPORATION

 

TABLE OF CONTENTS

 

  PAGE
PART I - FINANCIAL INFORMATION  
   
Item 1. Financial Statements (Unaudited) 3
  Balance Sheets at March 31, 2019 and September 30, 2018 4
  Statements of Operations for the three and six months ended March 31, 2019 and 2018 5
  Statements of Cash Flows for the six months ended March 31, 2019 and 2018 6
  Statement of Stockholders’ Equity for the six months ended March 31, 2019 and 2018 7
  Notes to Financial Statements 9
Item 2. Management Discussion & Analysis of Financial Condition and Results of Operations 13
Item 3 Quantitative and Qualitative Disclosures About Market Risk 15
Item 4. Controls and Procedures 15
     
PART II - OTHER INFORMATION  
   
Item 1. Legal Proceedings 17
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 17
Item 3. Defaults Upon Senior Securities 17
Item 4. Mining Safety Disclosures 17
Item 5 Other Information 17
Item 6. Exhibits 17
     
CERTIFICATIONS  
   
31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act
31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act
32.1 Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act
32.2 Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act

 

  2  

 

 

PART I

FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

The accompanying interim financial statements have been prepared in accordance with the instructions to Form 10-Q. Therefore, they do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders’ equity in conformity with accounting principles generally accepted in the United States of America. Except as disclosed herein, there has been no material change in the information disclosed in the notes to the financial statements included in the Company’s Annual Report on Form 10-K for the year ended September 30, 2018. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included, and all such adjustments are of a normal recurring nature. Operating results for the three and six months ended March 31, 2019 are not necessarily indicative of the results that can be expected for the year ending September 30, 2019 or any future period.

 

  3  

 

 

CIPHERLOC CORPORATION

CONDENSED BALANCE SHEETS

(UNAUDITED)

 

    March 31, 2019     September 30, 2018  
ASSETS                
Current assets                
Cash and cash equivalents   $ 11,090,605     $ 14,056,346  
Prepaid expenses     95,022        
Total current assets     11,185,627       14,056,346  
                 
Other assets     12,216       12,218  
Note receivable     401,000        
Fixed assets, net     53,073       20,050  
Total assets   $ 11,651,916     $ 14,088,614  
                 
LIABILITIES & STOCKHOLDERS’ EQUITY                
Current liabilities                
Accounts payable and accrued liabilities   $ 36,812     $ 52,043  
Accrued compensation     149,616       72,489  
Total current liabilities     186,428       124,532  
                 
Commitments and contingencies (Note 4)                
                 
Series A convertible preferred stock, $0.01 par value, 10,000,000 shares authorized; 1,000,000 issued and outstanding as of March 31, 2019 and September 30, 2018     10,000       10,000  
Common stock, $0.01 par value, 650,000,000 shares authorized; 40,792,510 and 40,743,917 issued and outstanding as of March 31, 2019 and September 30, 2018, respectively     407,925       407,438  
Additional paid-in capital     68,179,886       68,169,157  
Accumulated deficit     (57,132,323 )     (54,622,513 )
Total stockholders’ equity     11,465,488       13,964,082  
Total liabilities and stockholders’ equity   $ 11,651,916     $ 14,088,614  

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

  4  

 

 

CIPHERLOC CORPORATION

CONDENSED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

    Three Months Ended     Six Months Ended  
    March 31,     March 31,  
    2019     2018     2019     2018  
Revenues   $     $ 113,129     $     $ 228,771  
Cost of revenues           45,506             75,806  
Gross profit           67,623             152,965  
                                 
Operating expenses                                
General and administrative     505,807       230,366       1,038,781       414,286  
Sales and marketing     434,800       22,195       648,775       45,162  
Research and development     479,677       251,136       825,572       365,988  
Settlement expense           81,000             81,000  
Total operating expenses     1,420,284       584,697       2,513,128       906,436  
Operating loss     (1,420,284 )     (517,074 )     (2,513,128 )     (753,471 )
                                 
Other income (expense)                                
Gain (loss) on extinguishment of convertible note           66,912             (291,126 )
Excess fair value of derivatives in convertible note                       (486,745 )
Change in fair value of embedded conversion features in convertible notes           256,669               120,737  
                                 
Interest income (expense), net     2,421       (312,282 )     3,318       (508,318 )
Net loss   $ (1,417,863 )   $ (505,775 )   $ (2,509,810 )   $ (1,918,923 )
                                 
Net loss per common share – basic and diluted   $ (0.03 )   $ (0.03 )   $ (0.06 )   $ (0.16 )
                                 
Weighted average common shares outstanding – basic and diluted     40,786,279       17,806,123       40,774,152       12,228,585  

 

The accompanying notes are an integral part of these condensed unaudited financial statements.

 

  5  

 

 

CIPHERLOC CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

    Six Months Ended  
    March 31,  
    2019     2018  
CASH FLOWS FROM OPERATING ACTIVITIES:                
Net loss   $ (2,509,810 )   $ (1,918,923 )
Adjustments to reconcile net loss to net cash flows used in operating activities:                
Depreciation     4,036       2,608  
Stock-based compensation     11,216       167,743  
Stock issued for services     40,000        
Legal settlement           81,000  
Loss on extinguishment of convertible notes           291,126  
Excess fair value of derivatives in convertible note           486,745  
Change in fair value of embedded conversion features in convertible notes           (120,737 )
Debt discount amortization           482,935  
Changes in operating assets and liabilities:                
Prepaid expenses and other     (95,020 )      
Accounts payable and accrued liabilities     (15,231 )     (107,138 )
Accrued compensation     77,127          
Deferred revenue           (228,771 )
Net cash used in operating activities     (2,487,682 )     (863,412 )
                 
CASH FLOWS FROM INVESTING ACTIVITIES:                
Purchase of fixed assets     (37,059 )      
Funding of note receivable     (401,000 )      
Net cash used in investing activities     (438,059 )      
                 
CASH FLOWS FROM FINANCING ACTIVITIES:                
Common stock issued for cash           1,177,325  
Proceeds from convertible note, net           242,600  
Repayment of convertible notes           (350,000 )
Repayment of oversubscription     (40,000 )      
Net cash provided by (used in) financing activities     (40,000 )     1,069,925  
                 
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS     (2,965,741 )     206,513  
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD     14,056,346       227,396  
CASH AND CASH EQUIVALENTS, END OF PERIOD   $ 11,090,605     $ 433,909  
                 
Non-cash investing and financing activities:                
Conversion of debt into common stock   $     $ 77,500  
Conversion of preferred stock to common stock   $     $ 135,000  

 

The accompanying notes are an integral part of these condensed unaudited financial statements.

 

  6  

 

 

CIPHERLOC CORPORATION

CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY

(UNAUDITED)

 

    Preferred Stock     Common Stock     Additional Paid-in       Accumulated     Stockholders’  
    Shares     Amount     Shares     Amount     Capital     Deficit     Equity  
Balance at September 30, 2018     1,000,000     $ 10,000       40,743,917     $ 407,438     $ 68,169,157     $ (54,622,513 )   $ 13,964,082  
Common stock issued for services                 20,000       200       39,800             40,000  
Correction of shares outstanding                 19,247       193       (193 )            
Net loss                                   (1,091,947 )     (1,091,947 )
Balance at December 31, 2018     1,000,000       10,000       40,783,164       407,831       68,208,764       (55,714,460 )     12,912,135  
Common stock issued to an employee                 9,346       94       11,122             11,216  
Refund of oversubscription                             (40,000 )           (40,000 )
Net loss                                   (1,417,863 )   $ (1,417,863 )
Balance at March 31, 2019     1,000,000     $ 10,000       40,792,510     $ 407,925     $ 68,179,886     $ (57,132,323 )   $ 11,465,488  

 

The accompanying notes are an integral part of these condensed unaudited financial statements.

 

  7  

 

 

CIPHERLOC CORPORATION

CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY

(UNAUDITED)

 

    Preferred Stock     Common Stock     Additional Paid-in     Accumulated     Stockholders’  
    Shares     Amount     Shares     Amount     Capital     Deficit     Deficit  
Balance at September 30, 2017     10,000,000     $ 100,000       6,635,127     $ 66,351     $ 49,378,447     $ (50,201,730 )   $ (656,932 )
Common stock issued for cash                 37,000       370       56,830             57,200  
Common stock issued to officers and employees                 5,537       55       9,945             10,000  
Convertible notes – issuance of common stock                 362,500       3,625       498,875             502,500  
Convertible note – issuance of warrants                             90,345             90,345  
Convertible note – amendment of existing warrants                             74,041             74,041  
Net loss                                   (1,413,148 )     (1,413,148 )
Balance at December 31, 2017     10,000,000       100,000       7,040,164       70,401       50,108,483       (51,614,878 )     (1,335,994 )
Common stock issued for cash                 1,276,000       12,760       1,107,365             1,120,125  
Common stock issued to officers and employees                 82,917       829       156,914             157,743  
Settlement of convertible note                 50,000       500       77,000             77,500  
Common stock issued for legal settlement                 50,000       500       80,500             81,000  
Related party conversion of preferred stock     (9,000,000 )     (90,000 )     13,500,000       135,000       (45,000 )            
Net loss                                   (505,775 )     (505,775 )
Balance at March 31, 2018     1,000,000     $ 10,000       21,999,081     $ 219,990     $ 51,485,262     $ (52,120,653 )   $ (405,401 )

 

The accompanying notes are an integral part of these condensed unaudited financial statements.

 

  8  

 

 

CIPHERLOC CORPORATION

NOTES TO FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 1 – THE COMPANY

 

Cipherloc Corporation (the “Company” or “Cipherloc”) was incorporated in Texas on June 22, 1953 as American Mortgage Company. In March 2015, the Company changed its name to Cipherloc Corporation.

 

NOTE 2 - BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS

 

The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. The accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.

 

Operating results for the three and six months ended March 31, 2019 are not necessarily indicative of the results that may be expected for the year ending September 30, 2019 or any future period. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended September 30, 2018 have been omitted; this report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended September 30, 2018 included within the Company’s Form 10-K, as filed with the Securities and Exchange Commission.

 

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. Significant accounting policies are as follows:

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with a maturity at the time of purchase of three months or less to be cash equivalents. At March 31, 2019 and September 30, 2018, cash includes cash on hand and cash in the bank. The Company maintains its cash in accounts held by a large, globally recognized bank, and the balance of such accounts, at times, may exceed federally insured limits, as guaranteed by the Federal Deposit Insurance Corporation (“FDIC”). The FDIC insures these deposits up to $250,000. At March 31, 2019, $10,840,605 of the Company’s cash balance was uninsured.

 

  9  

 

 

Basic and Diluted Net Loss per Common Share

 

Basic net loss per share is computed by dividing net loss for the period by the weighted-average number of common shares outstanding during the reporting period. The weighted-average number of shares is calculated by taking the number of shares outstanding and weighting them by the amount of time that they were outstanding. Diluted net loss per share reflects the potential dilution that could occur if stock options, warrants, and other commitments to issue common stock were exercised or equity awards vest, resulting in the issuance of common stock that could share in the earnings of the Company. As of March 31, 2019 and September 30, 2018, the Company had 1,000,000 shares of preferred stock outstanding, which are convertible into 1,500,000 shares of common stock.

 

Diluted net loss per share is the same as basic net loss per share during periods where net losses are incurred because the inclusion of the potential common stock equivalents would be anti-dilutive as a result of the net loss. During the three and six months ended March 31, 2019, 25,015,866 warrants and 1,500,000 shares of convertible preferred stock were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. During the three and six months ended March 31, 2018, 1,241,000 warrants to purchase common stock and 1,500,000 shares of convertible preferred stock were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.

 

Research and Development and Software Development Costs

 

The Company expenses all research and development costs, including patent and software development costs.

 

Adoption of Recent Accounting Standard

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) . Under this guidance, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. The Company adopted ASU No. 2014-09 on October 1, 2018, and the adoption did not have a material impact on the Company’s financial statements or related disclosures.

 

Recent Accounting Pronouncements

 

The FASB issues ASUs to amend the authoritative literature in the ASC. There have been a number of ASUs to date that amend the original text of the ASC. Other than those discussed below, the Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Early adoption of the amendments in this standard is permitted for all entities, and the Company may recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements , to provide a new transition method and practical expedient for separating components of a contract. The amendments in this standard are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently in the process of evaluating the effect this ASU will have but expect to record a right of use asset and a lease liability equal to the value of the lease payments, reduced by using the rate inferred in the lease.

 

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurements (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement , to modify the disclosure requirements for fair value measurements. The ASU removes certain disclosure requirements related to transfers between fair value hierarchy levels and valuation processes for Level 3 fair value measurements. It modifies certain disclosure requirements for investments in entities that calculate net asset value. It adds certain disclosure requirements regarding gains and losses for recurring Level 3 fair value measurements and unobservable inputs used to develop Level 3 fair value measurements. ASU No. 2018-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company is currently in the process of evaluating the effect this ASU will have on its financial statements and related disclosures.

 

  10  

 

 

In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718) – Improvements to Nonemployee Share-Based Payment Accounting , to expand the scope of ASC Topic 718, Compensation – Stock Compensation , which currently only includes share-based payments to employees, to include share-based payments issued to nonemployees for goods or services. Thus, accounting for share-based payments to nonemployees and employees will be substantially aligned. ASU No. 2018-07 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently in the process of evaluating the effect this ASU will have on its financial statements and related disclosures.

 

NOTE 4 – NOTES RECEIVABLE

 

The Company advanced $401,000 to Quality Health Care International, LLC (“QHC”) during the quarter ended March 31, 2019. Subsequent to March 31, 2019, the Company advanced an additional $15,000. As of May 30, 2019, the Company executed a note receivable with QHC in the amount of $416,000. The note provides that if the funds are repaid within one year of the date of the note any interest charge will be waived. Beyond one year, the note will bear interest at the rate of 4% annuum. The due date of the note is on or before May 29, 2021. The effect of the waived interest is deemed to be de minimis. The purpose of the funds is to expedite training and development of a marketing program within QHC to sale the Company’s product to QHC’s hospital networks. The Company also entered into a Reseller Agreement with QHC as of May 30, 2019.

 

NOTE 5 – COMMITMENTS AND CONTINGENCIES

 

Litigation

 

The Company is currently not involved in any litigation that it believes could have a material adverse effect on its financial condition or results of operations. A disgruntled former consultant has brought an action in Texas state court against the Company and its chief executive officer, alleging fraud and misrepresentation pertaining to stock and payments alleged to be owed to the consultant. The Company has made all required payments and delivered the stock to the consultant. The consultant has also included a claim of partial ownership of some of the Company’s patents, which is without merit in that any interest he may have had has been assigned to the Company. The claim is frivolous and without merit. The case is being vigorously defended on the Company’s behalf by its insurance carrier.

 

Leases

 

In March 2019, the Company guaranteed a lease on behalf of Ageos, LLC, a sales representative assisting the Company with securing contracts with agencies of the United States government. The lease has a term of three years for 4,359 square feet of space in McClean, Virginia. The initial rent cost is $7,991 per month and the lease agreement provides for annual rent increases of approximately 4.0%. The amount of future payments guaranteed is $291,364. The nature of the guarantee and the operating agreement with Ageos, as discussed below, makes Cipherloc primarily responsible for the lease. As such, lease payments and lease obligations will be shown in the financial statements of Cipherloc.

 

In February 2019, the Company and the landlord for its leased office space in Buda, Texas entered into a new lease agreement, and the Company reduced its rented space from approximately 3,900 to 1,302 square feet. The new lease was effective February 1, 2019 and has a three-year term. The initial monthly rent is $2,566, and the lease agreement provides for annual rent increases of approximately 2.7%. The lease automatically renews for a three-year term, unless either party to the lease agreement notifies the other of the intent to terminate the lease in writing at least 180 days prior to the expiration of the current term.

 

In February 2019, the Company terminated its lease agreement for 1,005 square feet of office space on Butherus Drive in Scottsdale, Arizona effective March 1, 2019. In exchange for the lease termination, the Company relinquished its right to payments it had made to prepay rent through October 31, 2019. As a result of the termination, the Company recorded a charge to rent expense of approximately $13,000.

 

In October 2018, the Company leased approximately 3,900 square feet of office space on North Scottsdale Road in Scottsdale, Arizona. The lease for this facility began on October 4, 2018 and continues until October 31, 2021. Annual rent of $77,180 was prepaid for the first year from November 1, 2018 to October 31, 2019, and the lease agreement provides for annual rent increases of approximately 5.0%.

 

Ageos, LLC Operating Agreement

 

In the quarter ended March 31, 2019, the Company paid Ageos, LLC, a newly formed separate entity, approximately $700,000. The purpose of the funds was to establish an office in McLean, Virginia and to develop the resources and personnel to market the Company’s products to governmental sources, primarily requiring advanced security clearances that the Company does not currently have. On April 24, 2019 the Company entered into an Operating Agreement with Ageos that provides for how revenues will be shared from sales derived from the Company’s products. The advances through March 31, 2019 have been expensed as incurred in the accompanying statements of operations.

 

As Ageos is a newly formed venture, designed primarily to work with the Company in marketing its products, management is in the process of determining if Ageos represents a Variable Interest Entity that must be consolidated with the operations of the Company. The Company has expensed all advances to date, which largely represent non-capitalizable expenditures, and consequently believes that consolidation would not change the reported results of operations for the quarter ended March 31, 2019.

 

  11  

 

 

NOTE 6 - STOCKHOLDERS’ EQUITY

 

The Company is authorized to issue 650,000,000 common shares and 10,000,000 preferred shares at a par value of $0.01 per share.

 

Common Stock

 

Management determines the fair value of stock issuances using the closing stock price on the grant date.

 

During the six months ended March 31, 2019, the Company issued 20,000 shares of common stock with a fair value of $40,000 to Pycnocline, LLC for management consulting services, which was recorded in research and development expense.

 

During the six months ended March 31, 2019, the Company issued 9,346 shares of common stock with a fair value of $11,216 to an employee, which was recorded as stock-based compensation expenses in research and development expense in the statement of operations.

 

During the six months ended March 31, 2019, the Company refunded $40,000 for common stock, due to these funds exceeding the latest private placement offering maximum requirement allowed.

 

Preferred Stock

 

Each share of preferred stock is convertible into the Company’s common stock at a rate of one preferred share to 1.5 common shares. Each share of preferred stock has 1.5 votes on all matters presented to be voted by the holders of common stock. The holders of preferred stock can only convert the shares upon approval of the Company’s board of directors. If declared by the board of directors, holders of preferred stock are entitled to receive dividends prior and in preference to any declaration or payment of any dividend on the common stock of the Company. In the event of liquidation or dissolution of the Company, holders of preferred stock shall be paid out of the assets of the Company prior and in preference to any payment or distribution to holders of common stock of the Company.

 

NOTE 7- SUBSEQUENT EVENTS

 

On April 24, 2019 the Company entered into an Operating Agreement with Ageos, LLC a Virginia Limited Liability Company. The Operator has the required expertise, clearances and credentials to work with certain US government departments, agencies and affiliates; and the Operator will assist the Company in securing sales to the US Government and other contracts. The Company’s products will be sold to the Government at our normal pricing and the Company agreed to guarantee the lease for the secured facility in Virginia and to advance the cost at an amount not to exceed $1.6 million annually including the lease guarantee. The advanced funds will be reimbursed to the Company from Ageos’ profits generated by Ageos sales of the Company’s products. The Company chose to report payments to Ageos, LLC as an operational expense but did give separate disclosure consideration to reporting it as a Variable Interest Entity relationship.

 

On June , 2019 the Company executed an exclusive Reseller Agreement with Quality Health Care International, LLC  a Nevada Limited Liability Company a very experienced supplier of software to the healthcare industry in the United States and in other countries. The agreement is for a five year period with automatic renewals unless cancelled by either party. The market is the Healthcare industry in the United States and its territories. Other countries may be added in the future. The products to be licensed are those designed for commercial use, which are beneficial for the healthcare industry and will be sold at our normal pricing. The Company advanced cost in the amount of $416,000 to the Reseller which is evidenced by a two-year promissory note executed by the Reseller.

 

  12  

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

In this Quarterly Report, “Cipherloc,” “Company,” “our company,” “us,” and “our” refer to Cipherloc Corporation, unless the context requires otherwise.

 

Forward-Looking Statements

 

The following information contains certain forward-looking statements. Forward-looking statements are statements that estimate the happening of future events and are not based on historical fact. Forward-looking statements may be identified by the use of forward-looking terminology, such as “may,” “could,” “expect,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “possible,” “should,” “continue,” or similar terms, variations of those terms or the negative of those terms. The forward-looking statements specified in the following information have been compiled by our management on the basis of assumptions made by management and considered by management to be reasonable. Our future operating results, however, are impossible to predict and no representation, guaranty, or warranty is to be inferred from those forward-looking statements.

 

Our Business

 

Cipherloc is a data security solutions company. We are developing a highly innovative, polymorphic encryption technology designed to enable an iron-clad layer of protection to be added to existing solutions. The Company plans to introduce an innovative and revolutionary new type of encryption technology with five international patents and four US patents. We expect to be the industry’s first “Polymorphic Cipher Engine,” called Cipherloc ® . We expect to offer the first secure commercially viable advanced “Polymorphic Key Progression Algorithmic Cipher Engine” (“PKPA”). This morphing cipher can be used in any commercial data security industry and/or in sensitive applications.

 

Results of Operations for the three and six months ended March 31, 2019 and 2018

 

Revenue decreased to zero from $113,129 and $228,771 for the three and six months ended March 31, 2019 and 2018, respectively. Similarly, cost of revenue decreased to zero from $45,506 and $75,806 for the three and six months ended March 31, 2019 and 2018, respectively. The decrease in revenue and cost of revenue for each of the periods was a result of a software license contract ending in June 2018.

 

General and administrative expenses were $505,087 and $230,366 for the three months ended March 31, 2019 and 2018, respectively. General and administrative expenses were $1,038,781 and $414,286 for the six months ended March 31, 2019 and 2018, respectively. The increases in general and administrative expenses for the three and six-month periods primarily resulted from higher professional fees, including for legal and accounting, higher consulting and contract services, higher salaries and higher rent expense.

 

Sales and marketing expenses increased to $434,800 from $22,195 for the three months ended March 31, 2019 and 2018, respectively. Sales and marketing expenses increased to $648,775 from $45,162 for the six months ended March 31, 2019 and 2018, respectively. Sales and marketing expenses increased for the three and six-month periods ended March 31, 2019 primarily due to higher consulting fees to outside sales representation companies and sales consultants. We paid approximately $325,000 of consulting fees to Ageos, LLC (Ageos) for Ageos to establish operations to assist us with securing contracts with agencies of the United States government. In addition, we paid approximately $401,000 to Quality Health Care to establish operations to resell our products in the Health Care industry in the United States and its territories. The advanced funds are evidenced by a Promissory note in favor of the Company. The funds paid to these sales representatives will expectantly be recovered and remitted to us from profits generated by sales of our products by these representatives. We also have increased the number of sales consultants in the United States during 2019.

 

Research and development costs were $479,677 and $251,136 for the three months ended March 31, 2019 and 2018, respectively. Research and development costs were $825,572 and $365,988 for the six months ended March 31, 2019 and 2018, respectively. Research and development expenses increased for the three and six-month periods ended March 31, 2019 primarily as a result of higher salaries and consulting costs, partially offset by lower stock-based compensation.

 

  13  

 

 

Interest income, net, was $2,241 and $3,318 for the three and six months ended March 31, 2019, respectively. Interest expense, net, was $312,282 and $508,318 for the three and six months ended March 31, 2018, respectively. The change in interest income (expense), net, was due to the convertible notes with FirstFire Global Opportunities Fund, LLC and Peak One Opportunity Fund LP, which were outstanding during the six months ended March 31, 2018 and settled in March 2018 and April 2018, respectively.

 

Liquidity and Capital Resources

 

We had an accumulated deficit at March 31, 2019 of $57,132,323. We expect to incur substantial expenses and generate continued operating losses until we generate revenues sufficient to meet our obligations. At March 31, 2019, the Company had cash of $11,090,605. We believe that our existing cash will be sufficient to fund future operations for at least the next 12 months.

 

Cash Flow

 

The following table summarizes, for the periods indicated, selected items in our condensed statements of cash flows:

 

    Six Months Ended  
    March 31,  
    2019     2018  
Net cash (used in) provided by:                
Operating activities   $ (2,487,682 )   $ (863,412 )
Investing activities   $ (438,059 )   $  
Financing activities   $ (40,000 )   $ 1,069,925  

 

Operating Activities

 

Cash used in operating activities for the six months ended March 31, 2019 primarily resulted from the net loss of $2,509,810 and a net change of $33,124 in operating assets and liabilities, which was partially offset by the effects of non-cash charges of $55,252. Cash used in operating activities for the six months ended March 31, 2018 primarily resulted from the net loss of $1,918,923 and a net change of in operating assets and liabilities of $335,909, which was partially offset by the effects of non-cash charges of $1,391,420.

 

Investing Activities

 

Cash used in investing activities for the six months ended March 31, 2019 was for the purchase of fixed assets and for the cash the Company advanced to Quality Health Care International, LLC in the amount of $401,000.

 

Financing Activities

 

Cash used in financing activities for the six months ended March 31, 2019 was for refunds to investors of proceeds from the financing completed in August 2018. Cash provided by financing activities for the six months ended March 31, 2018 included $1,177,325 in proceeds from the issuance of common stock and $242,600 in proceeds from the issuance of convertible notes, which was partially offset by $350,000 in repayments of convertible notes.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements, including arrangements that would affect the liquidity, capital resources, market risk support, and credit risk support or other benefits.

 

WHERE YOU CAN FIND MORE INFORMATION

 

You are advised to read this quarterly report on Form 10-Q in conjunction with other reports and documents that we file from time to time with the SEC. In particular, please read our quarterly reports on Form 10-Q, annual report on Form 10-K, and current reports on Form 8-K that we file. Our website address is www.cipherloc.net. The information in our website is not incorporated by reference into this report. Through a link on the Investor section of our website, we make available our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as soon as reasonably practicable after they are filed with, or furnished to, the Securities and Exchange Commission, or SEC. You can also read any materials submitted electronically by us to the SEC on its website (www.sec.gov), which contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us.

 

  14  

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable

 

ITEM 4. CONTROLS AND PROCEDURES

 

This report includes the certifications of our Chief Executive Officer and Chief Financial Officer required by Rule 13a-14 of the Securities Exchange Act of 1934 (the “Exchange Act”). See Exhibits 31.1 and 31.2. This Item 4 includes information concerning the controls and control evaluations referred to in those certifications.

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s (the “SEC”) rules and forms and that such information is accumulated and communicated to our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures were designed to provide reasonable assurance that the controls and procedures would meet their objectives.

 

As required by SEC Rule 13a-15(b), our Chief Executive Officer and Chief Financial Officer need to carry out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report.

 

Management’s Report on Internal Control over Financial Reporting

 

Our Chief Executive Officer and the Chief Financial Officer are responsible for establishing and maintaining adequate internal control over financial reporting and for the assessment of the effectiveness of our internal control over financial reporting. Internal control over financial reporting (as defined in Rules 13a-15(f) and 15d(f) under the Exchange Act) is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with U.S. GAAP. Internal control over financial reporting includes those policies and procedures that (a) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of assets, (b) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (c) provide reasonable assurance that receipts and expenditures are being made only in accordance with appropriate authorization of management and the Board of Directors, and (d) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on the financial statements.

 

In connection with the preparation of our Annual Report on Form 10-K for the year ended September 30, 2018, our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of our internal control over financial reporting as of September 30, 2018 and concluded that we did not maintain effective internal control over financial reporting as of September 30, 2018 due to the identification of material weaknesses. We intend to remediate these material weaknesses during the 2019 fiscal year.

 

  15  

 

 

Changes in Internal Control over Financial Reporting

 

We intend to begin implementing a remediation plan to address the material weaknesses identified during the year ended September 30, 2018. The remediation efforts will focus on:

 

  Enhancing monitoring and review controls over financial reporting and disclosures;
     
  Enhancing review and approval controls around transaction processing;
     
  Enhancing controls around proving the delivery of software; and
     
  Enhancing and maintaining written policies and procedures for accounting and financial reporting.

 

We expect that remediation, including testing of related controls, will be completed during the balance of the 2019 fiscal year.

 

Inherent Limitations on Internal Controls

 

It should be noted that any system of controls, however well designed and operated, can provide only reasonable and not absolute assurance that the objectives of the control system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of certain events. Limitations inherent in any control system include the following:

 

  Judgments in decision-making can be faulty, and control and process breakdowns can occur because of simple errors or mistakes;
     
  Controls can be circumvented by individuals, acting alone or in collusion with others, or by management override;
     
  The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions;
     
  Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with associated policies or procedures; and
     
  The design of a control system must reflect the fact that resources are constrained, and the benefits of controls must be considered relative to their costs.

 

Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

 

  16  

 

 

PART II

OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

See “Litigation” in Note 4 – Commitments and Contingencies of the Notes to the Financial Statements in Part I, Item I of this document.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None

 

ITEM 4. MINING SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

There is no information with respect to which information is not otherwise called for by this form.

 

ITEM 6. EXHIBITS

 

3.1 Articles of Incorporation Incorporated by reference to the Registrant’s Form 10-SB filed on or about January 3, 2000.
3.2 Bylaws Incorporated by reference to the Registrant’s Form 10-QSB for the quarter ended December 31, 2000 and filed on or about February 14, 2001.
3.3 Amendment to the Articles of Incorporation indicating name change and reverse stock split as set out in Registrant’s Form 8-K dated and filed on March 23, 2015.
3.4 Amendment to the Registrant’s Bylaws as set out in Form 8-K filed on September 9, 2014 and inadvertently marked as exhibit 3.5.
4.1 S-8 Registration Filed on June 2, 2014 and by reference incorporated herein.
4.2 S-8 Registration Filed on October 27, 2016 and by reference incorporated herein.
4.3 Form S-1 Registration Statement filed on February 7, 2019 and amended on February 21, 2019 and by reference incorporated herein.
5.1 Legal opinion of Carl P. Ranno included in the S-8 Registration filed on June 2, 2014.
5.2 Legal opinion of Carl P. Ranno included in the S-8 Registration filed on October 27, 2016.
10.27 Employment agreement of Mike Hufnagel dated October 31, 2017 appointing him as Chief Operating Officer, incorporated by reference to the Registrant’s Form 8-K filed on October 31, 2017.
10.28 Employment Agreement of Dr. Milton Mattox date June 25, 2018 appointing him as Vice President of Sales and Marketing incorporated by reference to the Registrant’s Form 8-K filed on June 27, 2018.
10.29 Lease agreement effective July 15, 2018 for property in Scottsdale, AZ, incorporated by reference to the Registrant’s Form 10-Q for the quarter ending June 30, 2018 and filed on August 14, 2018.
10.30 Employment Agreement of Dr. Milton Mattox date September 24, 2018 appointing him as Chief Operating Officer incorporated by reference to the Registrant’s Form 8-K filed on September 26, 2018. The exhibit was inadvertently marked as Exhibit 10.29.
10.31 Lease agreement effective November 1, 2018 and dated October 4, 2018 for property in North Scottsdale, AZ incorporated by reference to the Registrant’s Form 8 K filed on October 11, 2018.
10.32 Placement Agent Agreement dated January 17, 2018 incorporated by reference to the Registrant’s Form 8-K filed on August 1, 2018.
10.33 2019 Stock Option/Stock Issuance Plan dated August 27, 2018 is incorporated by reference Registrant’s Form 10-Q for the quarter ending December 31, 2018 and filed on February 14, 2019.

 

  17  

 

 

10.34 Lease termination Agreement for property located on Butherus Drive in Scottsdale, AZ with an effective date of March 1, 2019, incorporated by reference to the Registrant’s Form 8 K filed on March 1, 2019.
10.35 Lease Reduction Agreement for property located in Buda ,TX with an effective date of February1, 2019, incorporated by reference to the Registrant’s Form 8 K filed on March 1, 2019.
10.36 Marketing Consulting Services Agreement was executed by the Registrant on March 29, 2019 and incorporated by reference to the Registrant’s Form 8-K filed on April 2, 2019. The Exhibit was inadvertently marked as exhibit 10.34.
10.37 Employment Agreement of James W. Sullivan appointing him as Chief Financial Officer effective April 15, 2019 and incorporated by reference to the Registrant’s Form 8-K filed on April 17, 2019. The Exhibit was inadvertently marked as exhibit 10.35.
10.38

Operating Agreement with Ageos, LLC effective April 24, 2019 and incorporated by reference to the Registrant’s Form 8-K filed on April 30, 2019

10.39

Employment Agreement of Gino J. Mauriello, CPA appointing him as Chief Financial Officer effective on May 19, 2019 and referenced in the Registrant’s Form 8-K filed on May 21, 2019. The Exhibit is attached hereto

10.40

Reseller Agreement with Quality Health Care International, LLC and Promissory Note dated May 30, 2019 and attached hereto.

14. Code of Ethics Incorporated by reference to the Registrant’s Form 10QSB for the quarter ending June 30, 2004 filed on or about August 16, 2004.
16.1 Letter of GBH CPA, PC regarding change in Independent Registered Public Accounting firm dated April 7, 2015, incorporated by reference to the Registrant’s Form 8-K filed on April 10, 2015.
16.2 Letter of MaloneBailey, LLP, regarding change in Independent Registered Public Accounting firm dated April 22, 2016, incorporated by reference to the Registrant’s Form 8-K filed on April 25, 2016.
16.3 Letter of dbbmckennon, regarding change in Independent Registered Public Accounting firm dated August 30, 2018 incorporated by reference to the Registrant’s Form 8-K filed on September 5, 2018. The exhibit was inadvertently marked as exhibit 16.2.
17.1 Letter of Resignation as Officer and Director dated December 30, 2014, incorporated by reference to the Registrant’s Form 8-K filed on January 2, 2015.
17.2 Appointment of two Directors one of which is also appointed as Chief Financial Officer on January 7, 2015 as incorporated by reference to the Registrant’s Form 8-K filed on January 8, 2015.
17.3 Letter of Resignation of Michael Hufnagel as Chief Operating Officer as Officer dated September 21, 2018, incorporated by reference to the Registrant’s Form 8-K filed on September 24, 2018.
17.4

Letter of Resignation of James W. Sullivan as the Chief Financial Officer dated May 12, 2019 incorporated by reference to the Registrant’s Form 8-K filed on May 21, 2019.

17.5

Letter of resignation of Independent Registered Public Accounting firm dated May 17, 2019 incorporated by reference to the Registrant’s Form 8-K filed on May 22, 2019.

17.6

Appointment of a Director on May 21, 2019 as incorporated by reference to the Registrant’s Form 8-K filed on May 23, 2019.

31.1 Certification of Chief Executive Officer Pursuant to the Securities Exchange Act of 1934, Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Certification of Chief Financial Officer Pursuant to the Securities Exchange Act of 1934, Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

  18  

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Registrant Cipherloc Corporation
     
Date: June 5, 2019 By: /s/ Michael De La Garza
    Michael De La Garza
    Chairman, Chief Executive Officer (Principal Executive Officer), President

 

  19  

 

 

 

Exhibit 10.39

 

 

EMPLOYMENT AGREEMENT

 

THIS EMPLOYMENT AGREEMENT (“Agreement”) is made, entered into, and effective as of May 19, 2019 (the “Effective Date”), by and between Cipherloc Corporation a Texas Corporation, with its principal place of business located at 825 Main Street, Suite 100 Buda, TX 78610 (“Company”), and Gino J. Mauriello, CPA an individual located at 6469 Almaden Expressway, Suite 80-129, San Jose, CA 95120, (“Employee”) (individually, a “Party”; collectively, the “Parties”).

 

RECITALS

 

WHEREAS, Company desires to employ Employee, and Employee desires to be employed as Chief Financial Officer, and;

 

WHEREAS, Company desires to have an employment agreement with Employee as its Chief Financial Officer, subject to the terms and conditions of this Agreement, and;

 

NOW, THEREFORE, in consideration of the mutual covenants and conditions contained herein, the Parties hereto hereby agree as follows:

 

AGREEMENT

 

1. Term of Employment.

 

a. Specified Period. Company hereby employs Employee and Employee accepts employment with Company for a period of three years beginning on May 19, 2019 and terminating on May 17, 2022.

 

b. Renewal. This Agreement is subject to automatic renewal upon the same terms and conditions as set forth herein, unless either this Agreement is terminated pursuant to Section 8 hereof or a Party gives written notice to the other Party of its intent to terminate, at least 30 days prior to expiration of the then-current term.

 

c. Employment Term Defined. “Employment term” refers to the entire period of employment of Employee by Company, whether for the period provided above, or whether terminated earlier as hereinafter provided or extended by mutual agreement between Company and Employee.

 

1
 

 

2. Duties and Obligations of Employee .

 

Employee shall serve as Chief Financial Officer and shall report to the President. Employee may work from his home office. Employee shall faithfully and diligently perform all services and duties as may be requested and required of Employee by the President. Employee shall devote such time and attention on an exclusive basis to oversee the Company’s Financial and Accounting operations. Employee at all times during the employment term shall strictly adhere to and obey all policies, rules and regulations established from time to time governing the conduct of employees of the Company.

 

3. Exclusivity, Non-Disclosure .

 

a. Devotion to Company Business. Employee agrees to perform Employee’s services efficiently and to the best of Employee’s ability. Employee agrees throughout the term of this Agreement to devote his time, energy and skill to the business of the Company and to the promotion of the best interests of the Company.

 

b. Trade Secrets. Employee agrees that he shall not at any time, either during or subsequent to his employment term, unless expressly consented to in writing by Company, either directly or indirectly use or disclose to any person or entity any confidential information of any kind, nature or description concerning any matters affecting or relating to the business of Company, including, but not limited to, information concerning the customers of Company, Company’s marketing methods, compensation paid to employees, independent contractors or suppliers and other terms of their employment or contractual relationships, financial and business records, know-how, or any other information concerning the business of Company, its manner of operations, or other data of any kind, nature or description. Employee agrees that the above information and items are important, material and confidential trade secrets and these affect the successful conduct of Company’s business and its goodwill.

 

c. Inventions and Patents . Employee agrees to disclose and to assign immediately to the Company, or to any persons designated by the Company, or at the Company’s option, any of the Company’s successors or assigns, all inventions or improvements which are or were made, conceived or reduced to practice by Employee, whether acting independently or with others, during the course of Employee’s employment with the Company, and which (i) were made, conceived of or first reduced to practice in the performance of any duties assigned to or undertaken by the Employee as an employee of the Company; or (ii) were made, conceived of or first reduced to practice with the use of the Company’s time, material, facilities or funds.

 

d. Third Party Information. Employee recognizes that the Company has received and, in the future, will receive from third parties their confidential or proprietary information subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. Employee agrees to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation or to use it except as necessary in carrying out Employee’s work for the Company consistent with the Company’s agreement with such third party.

 

2
 

 

e. Conflicting Employment. Employee agrees that, during the term of his employment with the Company, Employee will devote his full time and efforts to the Company, and he will not engage in any other employment, occupation or consulting activity that conflict with Employee’s obligations to the Company without written consent of the Company.

 

f. Solicitation of Employees. By executing this Employment Agreement Employee agrees that for a period of eighteen (18) months immediately following the termination of Employee’s relationship with the Company for any reason, whether with or without good cause or for any or no cause, at the option either of the Company or Employee, with or without notice, Employee will not hire any employees of the Company and will not, either directly or indirectly, solicit, induce, recruit or encourage any of the Company’s employees to leave their employment, or take away such employees, or attempt to solicit, induce, recruit, encourage or take away employees of the Company, either for Employee or for any other person or entity.

 

g. Noncompetition Covenants . Employee further agrees that during the period of employment by the Company and for a period of two (2) years thereafter, regardless of the reason for the termination of such employment, Employee will not, directly or indirectly, whether alone or as a partner, joint venture, officer, director, consultant, employee, independent contractor or stockholder of any company or business organization, engage in any business activity and/or accept employment with any person or entity, which is or may be directly or indirectly in competition with the products or services being marketed, promoted, distributed, developed, planned, sold or otherwise provided by the Company. The ownership by Employee of not more than one percent of the shares of capital stock of any corporation having a class of equity securities traded on a national securities exchange shall not be deemed, in and of itself, to violate this section.

 

4. Compensation .

 

  a. Salary. Subject to the termination of this Agreement as provided herein, Company shall compensate Employee for his services hereunder at an annual salary of $250,000.00 and payable in accordance with the Company’s practices, less normal payroll deductions, and prorated for the actual employment term.

 

  b. Salary Increases; Bonuses. Employee shall receive such annual increases in salary and such additional compensation as may be determined by the Board of Directors of the Company in its sole discretion. Such salary increases and/or additional compensation shall be paid to Employee on the anniversary date of this Agreement during the Employment Term, and at such other times as may be determined by the Board of Directors. Bonuses shall not exceed $50,000.

 

  c. Stock . Common stock shall be granted to Employee pursuant to the 2019 Stock Option/Stock Issuance Plan and the value of the common stock granted/issued shall not exceed the Employee’s annual Salary.

 

5. Employee Incentives. Employee shall be entitled to receive incentives including profit sharing, and any other incentive plans that the Company has or will make available to similarly situated employees.

 

3
 

 

6. Employee Benefits.

 

a. Vacation . Employee will be entitled, during each employment year, to 120 hours of paid time off (PTO) for vacation and sick leave up to a maximum number of hours equivalent to one year of hours available for accrual (120 hours). Employee may be absent from his employment for PTO only at such times as may be convenient to Company and Employee. Once the maximum number of hours is reached, all further accruals will cease. PTO accruals will recommence after time off is taken and the balance of accrued hours is less than the maximum number of hours.

 

b. Medical Coverage. Company agrees to include Employee in the coverage of its medical and dental insurance plan.

 

c. Plan Participation . Employee shall be entitled to participate in or to receive benefits under all of Company’s employee benefit plans made available by Company or in the future to similarly situated employees, subject to the terms, conditions and overall administration of such plans, including but not limited to 401(k) plans, IRA plans, E.R.I.S.A Plans, any other retirement or benefit plans that the Company has made available to similarly situated employees.

 

7. Business Expenses.

 

Employee will be required to incur travel, meals, entertainment and other business expenses on behalf of the Company in the performance of Employee’s duties hereunder. Company will reimburse Employee for all such reasonable business expenses incurred by Employee in connection with Company’s business upon presentation of receipts or other acceptable documentation of the expenditures. In compensating Employee for expenses, the ordinary and usual business guidelines and documentation requirements shall be adhered to by Company and Employee.

 

8. Termination of Employment.

 

(1) Termination for Cause . For purposes of this Agreement, “Cause” shall mean the occurrence of any one of the following events:

 

(a) Employee’s material breach of any provision of this Agreement or of Executive Employee Confidentiality, Non-Competition and Invention Assignment Agreement of even date herewith, entered into by and between the Company and Employee, which breach is not cured within ten days after the Company provides Employee with written notice of the nature and existence of such material breach;

 

(b) Employee’s willful refusal to obey written directions of Employee’s supervisor of the Company (so long as such directions do not involve illegal or immoral or otherwise improper acts), which refusal continues for a period of five business days after notice to Employee by the Company, and which notice references such refusal and this Section 8.

 

(c) Employee’s failure to perform Employee’s duties and responsibilities with diligence and in accordance with the productivity and quality requirements of the Company, which failure continues for a period of ten business days after written notice to Employee by the Company of Employee’s failure to perform; provided, however, that if Employee has been provided written notice pursuant to this Section 8 on two separate occasions during the Initial Term, any subsequent failure by Employee to perform Employee’s duties and responsibilities in accordance with the Company’s requirements shall constitute Cause and the Company shall not be required to provide any written notice or opportunity for Employee to correct Employee’s performance prior to a termination of Employee’s employment by the Company;

 

4
 

 

(d) Employee’s repeated refusal to comply with Company written policies or requirements which are adopted by the Board of Directors from time to time and which apply to Employee’s responsibilities;

 

(e) Employee’s action, or failure to act, in violation of any provision of the Company’s standard employee guidelines, including but not limited to any policy concerning sexual harassment, substance abuse, as such policies may be in effect from time to time, if such violation of the Company’s policy would generally result in the termination of employment of a Company employee;

 

(f) Fraud or dishonesty by Employee, in the good faith opinion of the Board of Directors of the Company; or

 

(g) If Employee is convicted or admits to the commission of a criminal offense or act of moral turpitude that constitutes a felony in the jurisdiction in which the offense is committed.

 

(h) The notice of termination required by this section shall specify the ground for the termination and shall be supported by a statement of all relevant facts.

 

(2). Termination Upon Death or Disability.

 

i. Death . This Agreement shall be terminated immediately upon the death of Employee.

 

ii. Disability . Company reserves the right to terminate this Agreement if, due to illness or injury, either physical or mental, Employee is unable to perform Employee’s customary duties as an employee of Company, unless reasonable accommodation can be made to allow Employee to continue working, for more than 30 days in the aggregate out of a period of 12 consecutive months. The disability shall be determined by a certification from a physician. Such a termination shall be effected by giving ten days’ written notice of termination to Employee. Termination pursuant to this provision shall not prejudice Employee’s rights to receive disability insurance payments or the continued compensation pursuant to this Agreement.

 

iii. Without cause. Termination under this section for either death or disability shall not be considered “for cause” for the purposes of this Agreement.

 

(3). Effect of Merger, Change of Control, Transfer of Assets, or Dissolution. Without the prior written consent of Employee, this Agreement shall not be terminated by any voluntary or involuntary dissolution of Company resulting from a merger, change of control (greater than the transfer of 45% of voting securities or consolidation in which Company is not the consolidated or surviving corporation), or a transfer of all or substantially all of the assets of Company. In the event of any such merger, change of control or consolidation or transfer of assets, Employee’s rights, benefits, and obligations hereunder shall be assigned to the surviving or resulting corporation or the transferee of Company’s assets, unless Employee agrees otherwise.

 

5
 

 

(4). Payment on Termination . If Company terminates this Agreement “without cause,” it shall pay “Severance Benefits” to the Employee. Severance Benefits shall mean, for purposes of this Agreement, a cash payment equal to the aggregate compensation payable to the Employee during the remaining term of this Agreement, including all salary, commissions, bonuses and other compensation. In the case of termination under section (8)(3), Severance Benefits will be, at a minimum, the value of Employee’s then annual salary.

 

(5). Termination by Employee .

 

i. Without Cause. Employee may terminate this Agreement without cause upon 30 days’ prior written notice to Company.

 

ii. With Cause. Employee may terminate this Agreement immediately with cause, in which event Employee shall receive the Payment on Termination in accordance with Section 8(4) herein. For the purposes of this Agreement, “cause” for termination by Employee shall be a breach of any material covenant or obligation hereunder; or the termination of this Agreement without the prior written consent of Employee due to the voluntary or involuntary dissolution of the Company, any merger or consolidation in which the Company is not the surviving or resulting corporation, or any transfer of all or subsequently all of the assets of Company.

 

9. General Provisions.

 

a. Binding Effect . This Agreement shall be binding upon and inure to the benefit of the Parties hereto their respective devisees, legatees, heirs, legal representatives, successors, and permitted assigns. The preceding sentence shall not affect any restriction on assignment set forth elsewhere in this Agreement.

 

b. Notices. Any notice, request, instruction, or other document required by the terms of this Agreement, or deemed by any of the Parties hereto to be desirable, to be given to any other party hereto shall be in writing and shall be given by personal delivery, overnight delivery, mailed by registered or certified mail, postage prepaid, with return receipt requested, or sent by facsimile/electronic transmission to the addresses of the Parties as follows:

 

To Company:  
   
  Cipherloc Corporation
  825 Main Street, Suite 100
  Buda, TX 78610
  Email:mdgl@Cipherloc.net
  Attn: President

 

6
 

 

To Employee:  
   
  Gino J. Mauriello
  1607 East Windmill Lane
  Las Vegas, NV 89123
  Email: gino@ginotax.com

 

The persons and addresses set forth above may be changed from time to time by a notice sent as aforesaid. If notice is given by personal delivery or overnight delivery in accordance with the provisions of this Section, such notice shall be conclusively deemed given at the time of such delivery provided a receipt is obtained from the recipient. If notice is given by mail in accordance with the provisions of this Section, such notice shall be conclusively deemed given upon receipt and delivery or refusal. If notice is given by facsimile/electronic transmission in accordance with the provisions of this Section, such notice shall be conclusively deemed given at the time of delivery if during business hours and if not during business hours, at the next business day after delivery, provided a confirmation is obtained by the sender.

 

c. Sums Due Deceased Employee. If Employee dies prior to the expiration of the employment term, any sums that may be due him from Company under this Agreement as of the date of death shall be paid to Employee’s executors, administrators, heirs, personal representatives, successors, and assigns.

 

d. Assignment . Subject to all other provisions of this Agreement, any attempt to assign or transfer this Agreement or any of the rights conferred hereby, by judicial process or otherwise, to any person, firm, Company, or corporation without the prior written consent of the other Party, shall be invalid, and may, at the option of such other Party, result in an incurable event of default resulting in termination of this Agreement and all rights hereby conferred.

 

e. Choice of Law . This Agreement and the rights of the parties hereunder shall be governed by and construed in accordance with the laws of the State of Texas including all matters of construction, validity, performance, and enforcement and without giving effect to the principles of conflict of laws.

 

f. Jurisdiction . The parties submit to the jurisdiction of the Courts of the State of Texas or a Federal Court impaneled in the State of Texas for the resolution of all legal disputes arising under the terms of this Agreement.

 

g. Indemnification . Company shall indemnify, defend and hold Employee harmless, to the fullest extent permitted by law, for all claims, demands, losses, costs, expenses, obligations, liabilities, damages, recoveries and deficiencies, including interest, penalties and reasonable attorney’s fees that Employee shall incur or suffer that arise from, result from or relate to the discharge of Employee’s duties under this Agreement. Company shall maintain adequate insurance for this purpose or shall advance Employee any expenses incurred in defending any such proceeding or claim to the maximum extent permitted by law.

 

7
 

 

h. Entire Agreement . Except as provided herein, this Agreement, including exhibits, contains the entire agreement of the Parties, and supersedes all existing negotiations, representations, or agreements and all other oral, written, or other communications between them concerning the subject matter of this Agreement. There are no representations, agreements, arrangements, or understandings, oral or written, between and among the Parties hereto relating to the subject matter of this Agreement that are not fully expressed herein.

 

i. Severability . If any provision hereof is held to be illegal, invalid or unenforceable under present or future laws effective during the term hereof, such provision shall be fully severable. This Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, and the remaining provisions hereof shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision or by its severance wherefrom. Furthermore, in lieu of such illegal, invalid or unenforceable provision there shall be added automatically by the Company as a part hereof a provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible and legal, valid and enforceable.

 

j. Captions . The captions in this Agreement are inserted only as a matter of convenience and for reference and shall not be deemed to define, limit, enlarge, or describe the scope of this Agreement or the relationship of the Parties, and shall not affect this Agreement or the construction of any provisions herein.

 

k. Modification . No change, modification, addition, or amendment to this Agreement shall be valid unless in writing and signed by all Parties hereto.

 

l. Attorneys’ Fees . In the event any Party hereto shall commence legal proceedings against the other to enforce the terms hereof, or to declare rights hereunder, as the result of a breach of any covenant or condition of this Agreement, the prevailing Party in any such proceeding shall be entitled to recover from the losing Party its costs of suit, including reasonable attorneys’ fees, as may be fixed by the court.

 

m. Taxes . Any income taxes required to be paid in connection with the payments due hereunder, shall be borne by the Party required to make such payment. Any withholding taxes in the nature of a tax on income shall be deducted from payments due, and the Party required to withhold such tax shall furnish to the Party receiving such payment all documentation necessary to prove the proper amount to withhold of such taxes and to prove payment to the tax authority of such required withholding.

 

n. Not for the Benefit of Creditors or Third Parties . The provisions of this Agreement are intended only for the regulation of relations among the Parties. This Agreement is not intended for the benefit of creditors of the Parties or other third Parties and no rights are granted to creditors of the Parties or other third Parties under this Agreement. Under no circumstances shall any third party, who is a minor, be deemed to have accepted, adopted, or acted in reliance upon this Agreement.

 

8
 

 

o. Counterparts . This Agreement may be executed in several counterparts and it shall not be necessary for each Party to execute each of such counterparts, but when all of the parties have executed and delivered one of such counterparts, the counterparts, when taken together, shall be deemed to constitute one and the same instrument, enforceable against each Party in accordance with its terms.

 

p. Facsimile Signatures . The parties hereto agree that this Agreement may be executed by facsimile signatures and such signatures shall be deemed originals. The parties further agree that within ten days following the execution of this Agreement, they shall exchange original signature pages.

 

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed as of the Effective Date.

 

  COMPANY:
   
  Cipherloc Corporation, a Texas Corporation
   
  /s/ Michael De La Garza
  By: Michael De La Garza
  Its: President/CEO
   
  EMPLOYEE:
   
  Gino J. Mauriello
   
  /s/ Gino J. Mauriello
  By: Gino J. Mauriello

 

9
 

 

 

 

Exhibit 10.40

 

 

RESELLER AGREEMENT

 

This Reseller Agreement (the “Agreement”) is made and entered into as of this 30th day of May 2019, by and between Cipherloc Corporation a Texas corporation, located at 825 Main Street, Suite 100, Buda, TX 78610 (“the Company”), and Quality Health Care International LLC, a Nevada limited liability company located at 192 Hanna Court, Mesquite, NV 89027 and its affiliate (individually, a “Party” and collectively, the “Parties”).

 

WHEREAS , Cipherloc desires to appoint Reseller as a reseller for the Products (as defined below) on an exclusive basis as to the customers as set forth in Schedule A; and

 

WHEREAS , Reseller desires to be appointed to distribute and resell such Products either on a standalone basis or in conjunction with Services (as defined below); and

 

NOW, THEREFORE , in consideration of the mutual covenants and agreements contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Reseller hereby agree as follows.

 

1. DEFINITIONS

 

In addition to the terms defined throughout this Agreement, the following definitions shall also apply:

 

1.1 Change of Control ” means the merger, consolidation or the sale of an entity to an unrelated third party, whether by (a) sale of securities (by the entity or its securities holders) which results in the securities holders of the entity immediately prior to such sale owning less than fifty percent (50%) of the voting securities of the entity immediately after such sale, or (b) sale of all or substantially all of the entity’s assets.

 

1.2 Effective Date ” means the date this Agreement is countersigned by an authorized representative of Cipherloc.

 

1.3 End User ” means anyone that is granted a right, license or sublicense to use the Products by or through Reseller solely for such End User’s internal business purposes and that cannot resell, lease, sublicense or otherwise distribute the Software to any other party.

 

1.4 EULA ” means Cipherloc’s form end user license agreement provided by Cipherloc with the Software Products to Reseller and subject to revision by Cipherloc from time to time. Where the EULA is provided embedded in the Software, a hard copy is available upon written request to Cipherloc.

 

1
 

 

1.5 Demonstration Software ” means free, limited-time versions of Products, including Software, which Cipherloc may provide as the Parties mutually agree.

 

1.6 Documentation ” means the documentation, manuals and other materials provided by Cipherloc to Reseller that relate to the Products, whether in printed form, electronic form, posted on Cipherloc’s website, available on-line or in any other format.

 

1.7 Intellectual Property Rights ” means all rights related to all information and know-how (whether or not confidential), trade secrets, works of authorship (whether or not copyrightable), patents, copyrights, trademarks, trade names, applications for any of the foregoing, ideas or concepts (whether or not patentable), or improvements, modifications or additions to any of the above, including, in the case of Cipherloc and its licensors, the Products.

 

1.8 Maintenance and Support Services ” means those maintenance and support services provided by Cipherloc to End Users, including but not limited to basic, standard product support provided by Cipherloc pursuant to the Cipherloc Support Terms, which may be modified, in Cipherloc’s sole discretion from time to time effective immediately upon posting to the Cipherloc’s website) and product support services provided by Cipherloc to End Users pursuant to an Cipherloc Professional Services Agreement.

 

1.9 Products ” means Software Licensing Agreements for its newly developed software known as CipherLoc Platform, Cipherloc Shield, Cipherloc SMS, Cipherloc SDK, Maintenance and Support Services, Documentation, and other materials and services made available by Cipherloc to Reseller pursuant to this Agreement and shall initially mean the Products specified on Schedule A. The Products available under this Agreement may be amended at any time by Cipherloc upon prior written notice to and agreement with Reseller.

 

1.10 Services ” means professional consulting, services to be offered to End Users in conjunction with the Products, including but not limited to Maintenance and Support Services.

 

1.11 Software ” means the software applications packages and all future derivations, upgrades and revisions thereto, in executable object code only, that are made commercially available by Cipherloc to its End Users in general releases from time to time.

 

1.12 Territory ” means the geographic areas specified on Schedule A .

 

2. GRANT OF LICENSE

 

2.1 Reseller License . Subject to the terms and conditions of this Agreement, Cipherloc grants to Reseller during the Term an exclusive, non-transferable right and license to market and distribute the Products, alone or in combination with Services offered by either Cipherloc or Reseller, directly to End Users for use solely within the Territory. Services to be provided directly by Reseller to End User in conjunction with the Products will be the subject of independent offerings by Reseller alone and will be governed solely by the terms and conditions of separate agreements entered into between Reseller and the End User. For Services provided directly by Cipherloc to End User, including but not limited to Maintenance and Support Services, the End User may be required, in Cipherloc’s sole discretion, to enter into an agreement directly with Cipherloc only, Reseller only, or both Cipherloc and Reseller. Reseller agrees to abide by Cipherloc’s direction on such End User contracting requirements for Services to be provided directly by Cipherloc to End User, provided such direction has been given in writing by Cipherloc to Reseller (which direction may be modified, in Cipherloc’s sole discretion and Reseller’s agreement, from time to time effective immediately upon receipt by Reseller.

 

2
 

 

2.2 Limitations on Distribution License . Reseller will have no rights to the Products except as set forth in this Agreement or a separate, written license agreement signed by Cipherloc. Reseller will not authorize or appoint any reseller, dealers, agents, representatives, sub-distributors, original equipment manufacturers, value-added resellers, systems integrators, or other third parties to market or distribute the Products without the prior written consent of Cipherloc. Reseller will have no rights to source code to the Software. Reseller will not cause or permit the recompilation, disassembly, reverse engineering or other decoding of the Products. Reseller will not replicate, produce, copy, or modify the Products (including any Demonstration Software), except as provided for in this Agreement or, if applicable, the EULA.

 

2.3 License Enforcement . Reseller shall use its best efforts to assist Cipherloc in the protection of Cipherloc’s legal rights relating to the Products, including without limitation, providing prompt written notice to Cipherloc of any known violations or breaches of any EULA and any infringement by third parties of Cipherloc’s Intellectual Property Rights. Reseller shall use its best efforts to cooperate with Cipherloc in any action by Cipherloc alleging any actual or threatened violation of Cipherloc’s Intellectual Property Rights.

 

3. PRODUCT ORDERS, SUPPLY, SHIPMENT AND CANCELLATION

 

3.1 Acceptance by Cipherloc . All orders placed with Cipherloc for Products shall be subject to acceptance by Cipherloc, in its sole discretion, at its principal place of business. All orders for Products must have a confirming purchase order number from Reseller.

 

3.2 Scope . The terms of this Agreement shall govern all purchase orders relating to the Products. The terms contained in succession documents which shall include, without limitation, acknowledgements, invoices or purchase orders, and the terms of any prior agreements between Cipherloc and Reseller related to the subject matter of this Agreement, are hereby superseded by the terms of this Agreement and any terms contained in such documents that are additional to or inconsistent with this Agreement shall have no force or effect, unless specifically agreed to in a writing signed by Cipherloc after the Effective Date.

 

3.3 Cancellation or Delay by Cipherloc . If Reseller fails to comply with any material term or condition of this Agreement, Cipherloc reserves the right to cancel or delay shipment of any order placed by Reseller and accepted by Cipherloc. Cipherloc will notify Reseller within five (5) days of receipt of a purchase order if it is unable to meet Reseller requested delivery date and provide Reseller with the delivery date or dates on which Cipherloc will be able to deliver the Products ordered; provided, however, Cipherloc shall not be liable, other than through its negligence, for any damages to Reseller or to any other person for Cipherloc’s delay in delivery or error in filling orders.

 

3.4 Shipment . All Products will be delivered to the destination designated on Reseller’s purchase order. Unless otherwise directed by Reseller in its purchase order, Cipherloc shall select a common carrier. Costs for shipment shall be added to the invoice as a separate line item and paid by Reseller.

 

3
 

 

3.5 Export Restrictions . Reseller acknowledges that all Products are subject to the export control laws and regulations of the United States, and any amendments thereto. Reseller confirms that it will not export or re-export the Products, any technical data received under or in connection with this Agreement, or any direct Product (including processes and services) produced by the use of any such technical data, directly or indirectly, to (i) any countries that are subject to United States export or (ii) to any End User whom Reseller knows or has reason to know will utilize them in the design, development or production of nuclear, chemical or biological weapons. In addition, if Cipherloc informs Reseller that, or Reseller knows or has reason to know that, any Product contains encryption or other capabilities subject to the International Traffic in Arms Regulations (ITAR) set forth at 22 C.F.R. section 120 et seq ., Reseller shall not export such Product in violation of ITAR.

 

3.6 Modifications to or Discontinuation of Products . Cipherloc may, at any time and in its sole discretion, discontinue distribution of or modify any or all Products or versions of Products, or discontinue support, maintenance, or the provision of new versions, updates, or corrections for any Product or version of a Product without liability. Cipherloc agrees to give Reseller at least ninety (90) days prior notice of any Product that Cipherloc will be discontinuing. Such notice may be given by Cipherloc in any form or manner, including but not limited to posting on Cipherloc’s website, delivery of an email or other written notification.

 

4. PRICES AND PAYMENTS

 

4.1 Resellers Price . Reseller shall receive the pricing discounts on the Products as specified in Schedule A , using the Cipherloc published Price List in effect at the time of the order. Prices or discounts specified on Schedule A and the Price List are subject to change upon ninety (90) days advance written notice of any change that results in a price increase. Any increase in price to Reseller shall only be effective for orders received after expiration of the ninety (90) days advance written notice. Decreases in price shall be effective immediately upon the date of the notice.

 

4.2 Discounts . Should Schedule A or the Price List contain volume discount provisions, Reseller covenants that it will not seek to circumvent such provisions by entering into cooperative buying agreements with other customers of Cipherloc.

 

4.3 Resale Product Prices . The prices for the Products listed in the Price List are suggested list prices. The parties acknowledge that Reseller shall be free to resell the Products at its own prices. No Cipherloc representative has the authority to require or suggest that Reseller charge a particular resale price for the Products which it purchases hereunder.

 

4.4 Payment . Unless otherwise agreed to by Cipherloc in writing, all payments shall be in U.S. currency. Payment for Products shall be due and paid net thirty (30) days from the date of delivery and receipt of an invoice from Cipherloc. A late payment charge of the lesser of one and one-half percent (1.5%) per month or the highest rate permitted by law shall be charged upon unpaid balances past due by more than thirty (30) days.

 

4.5 Taxes . Reseller is responsible for payment of any and all applicable taxes, other than Cipherloc’s net income taxes relating to the Products and this Agreement. Orders are subject to applicable sales, use and/or other such taxes unless a resale certificate is on file with Cipherloc. In the event Cipherloc is required to pay any applicable taxes with respect to any order made pursuant to this Agreement, Reseller shall pay any such taxes, as included on the invoice.

 

4
 

 

4.6 Expense Advances. Cipherloc has advanced $416,000 to the Reseller to assist in establishing the necessary technical staff, office and employees to successfully sell the Products in the Territory. The expense advances shall be reimbursed by Reseller from Reseller’s initial gross receipts, generated through the sale of the Products, until fully repaid pursuant to a Promissory Note attached as Exhibit A.

 

4.7 Audits . Reseller agrees to allow Cipherloc to examine such books, records and accounts at Reseller’s site to verify Reseller’s reports on the amount of payments made to Cipherloc under this Agreement. Such audits will be conducted monthly until the Expense Advances have been repaid in full. Thereafter on an annual basis upon fifteen (15) days prior written notice and shall occur during normal business hours. The cost of the audit shall be borne by Cipherloc unless the audit results reveals an underpayment of five-percent (5%) or more of the total amounts due to Cipherloc during the audited period, in which case the cost of such audit shall be paid by Reseller.

 

5. SERVICES, MARKETING AND OTHER REQUIREMENTS

 

5.1 Applicability of Product . Cipherloc shall have no liability for recommendations or misrepresentations made by Reseller to End Users and Reseller assumes responsibility for the selection and recommendation of the Products to achieve the desired results and business purposes of End Users.

 

5.2 End User . Should an End User request that Cipherloc intervene on such End User’s behalf with Reseller concerning Reseller’s provision of Services, Cipherloc and Reseller agree to use their commercially reasonable efforts to resolve such End User’s problems. Neither Cipherloc nor Reseller shall have any obligation to expend any expense or perform any services under this Section 5.2 unless otherwise agreed by the parties in a separate written agreement. End Users are not third party beneficiaries of this Section 5.2 .

 

5.3 Training . Reseller shall promptly complete all training requirements as set forth in Schedule B . Unless otherwise specified in writing by Cipherloc, all training shall be web based. If Cipherloc agrees to conduct training other than web-based training, Reseller shall pay Cipherloc all ancillary expenses associated with such training, including but not limited to, Cipherloc’s travel expenses.

 

5.4 Marketing . Reseller shall use its best efforts to promote and market the Products. Reseller shall provide sufficient qualified staff to carry out its obligation to actively market and solicit sales of Products. Reseller will include a representative listing of all Products in applicable catalogs and published price lists. Reseller will display and demonstrate appropriately configured Products. Within the time period specified on Schedule B , Reseller shall have at least the number of employees specified on Schedule B trained to demonstrate each Product.

 

5.5 Marketing Practices . At Cipherloc’s sole discretion, Cipherloc may provide Reseller with reasonable quantities (or master copies) of Cipherloc’s standard advertising and promotional materials, pricing information and technical data related to the Products (“Marketing Materials”). Reseller shall (a) perform its duties in a manner that will preserve the reputation and promote the goodwill, name and interests of Cipherloc and the Products; (b) avoid deceptive, misleading or unethical practices that are or might be detrimental to Cipherloc, the Products or the public including, but not limited to, disparagement of Cipherloc or the Products; (c) make no false or misleading representation with respect to the Products or Cipherloc; (d) not publish or use any misleading or deceptive advertising material; and (e) make no representations with respect to the Products or Cipherloc that are inconsistent with the Documentation, Marketing Materials and other literature distributed by Cipherloc, including all warranties, disclaimers, and support policies contained in such Documentation, Marketing Materials and other literature. In the event Reseller E, its officers, directors, agents or employees make any representation other than as permitted under this Agreement, Reseller agrees to indemnify Cipherloc as provided in Section 8.2. Except as otherwise provided herein, neither Cipherloc nor Reseller will publish, or cause or permit to be published, any advertising, press release or other material that refers in any way to the other party or the Products without the prior written permission of the other party ; provided, however that Cipherloc may use Reseller’s name and may disclose that Reseller is a reseller of the Products in Cipherloc advertising, promotions and similar public disclosures.

 

5
 

 

5.6 Program Requirements. Reseller acknowledges and agrees that Cipherloc may, at its sole discretion, discontinue or change at any time the Cipherloc Reseller program requirements (collectively, the “Program Requirements”), including without limitation adoption of separate policies and procedures containing Program Requirements. Cipherloc may notify Reseller of such changes by mail, by e-mail or by posting information on Cipherloc’s website. Such changes shall become effective thirty (30) days after Cipherloc’s providing such notice to Reseller and shall be automatically incorporated by reference into this Agreement. Notwithstanding the foregoing, should Cipherloc material change the Program Requirements, Reseller shall have the right during the thirty (30) day prior notice period for such material change to immediately terminate this Agreement upon written notice to Cipherloc.

 

6. PRODUCT SUPPORT

 

6.1 Product Performance . Cipherloc will use its commercially reasonable efforts to make the Products perform substantially in accordance with the product description set forth in the relevant Documentation that accompanies the Products, as it may exist from time to time. However, Reseller acknowledges that inevitably some errors may exist in the Products, and the presence of such errors and Cipherloc’s failure to correct such errors shall not be a breach of this provision.

 

6.2 Reseller Technical Support . Only Reseller engineers that have received training per Schedule B will be given access to Cipherloc’s standard technical support telephone line, along with access authorization for standard technical support. Cipherloc may provide on-site technical support, on a case-by-case basis, at Cipherloc’s then-current fees or for a fee mutually agreed to by Cipherloc and Reseller.

 

6.3 Discontinued Products . Cipherloc shall support withdrawn or discontinued versions of its Software for a period of at least six (6) months after its announced withdrawal or discontinuation. Communications between Cipherloc and Reseller regarding withdrawn or discontinued Software are considered Confidential Information under Section 11.1 and are subject to the terms of this Agreement.

 

6.4 Maintenance Services. Cipherloc shall provide Software Maintenance and Services for the Products directly to End Users so long as such End Users subscribe to Maintenance and Support Services and are in compliance with the applicable terms and conditions for such Maintenance and Support Services.

 

6
 

 

6.5 Web and Phone Support for Demonstration Software. During the Term, Cipherloc shall provide for the Demonstration Software (i) Web-based support, consisting of information on the most current release of the Demonstration Software through Cipherloc’s web site, including all available solutions and corrections for reported problems that are replicated and diagnosed by Cipherloc as defects in the Software.

 

6.6 Product Errors and Omissions—Notification . Reseller shall identify and promptly inform Cipherloc of any design or programming errors or omissions in the Products sold of which it becomes aware and consult with Cipherloc regarding necessary corrections and/or modifications. Such notification shall occur through Cipherloc’s web site.

 

7. INTELLECTUAL PROPERTY RIGHTS

 

7.1 Intellectual Property Rights . Reseller acknowledges that the Products and all related Intellectual Property Rights are owned by Cipherloc and that this Agreement grants no ownership rights to Reseller.

 

7.2 Limited Trademark License . At Cipherloc’s sole discretion, Cipherloc may grant to Reseller during the Term a non-exclusive, non-transferable, limited license to use in the Territory Cipherloc’s name, logo and other trademarks used by Cipherloc with respect to the Products (the “Trademarks”) solely in connection with the promotion of the Products and solely as pre-approved in writing by Cipherloc. Upon expiration or termination of this Agreement, Reseller agrees to cease all display, advertising and use of any Trademarks.

 

7.3 Copyright; Trademark; Proprietary Notices . Reseller agrees to maintain and preserve any copyright notices, trademark notices or any confidential or proprietary legends on all Products (including Demonstration Software).

 

8. INDEMNIFICATION

 

8.1 Mutual Indemnification — Violations of Law . Each party shall perform its duties in compliance with all applicable laws and shall hold the other party harmless and indemnify the other party for, from and against any loss, claim, damage, liability, or expense, including reasonable attorney’s fees, arising from any violation of law by such party.

 

8.2 Reseller Indemnification — Breach of Agreement . Reseller will defend and indemnify Cipherloc for, from and against, and hold Cipherloc and its officers, directors and employees harmless from, any and all losses, claims, damages, liabilities and expenses, including reasonable attorney fees and costs of litigation, resulting from (i) any improper acts or omissions by Reseller relating to its activities in connection with this Agreement, (ii) any breach by Reseller of any of its obligations under this Agreement, (iii) any violation of the Foreign Corrupt Practices Act (FCPA) including its accounting provisions, and (iv) any misrepresentations relating to Cipherloc, the Products, or this Agreement.

 

7
 

 

8.3 Cipherloc Indemnification – Infringement . Cipherloc agrees, for as long as copies of the Products sold by Reseller are in use by End Users licensed by Cipherloc through Reseller, to indemnify and hold Reseller and its officers, directors and employees harmless for, from and against any loss, claim, damage, liability, expense, or cost, including reasonable attorneys’ fees, arising out of any claim, demand, or suit to the extent a Product violates any copyright, patent, trade secret, trademark, or proprietary right existing under the laws of the United States or any state or territory thereof (“ Claim ”); provided that such indemnity shall not apply if (i) the violation arises out of use of the Products in combination or in connection with other products or components, and such violation would not have existed from use of the Products on a stand-alone basis, (ii) the violation arises out of modifications made to the Products other than by Cipherloc, (iii) Reseller’s failure to implement enhancements as required by Cipherloc. Cipherloc shall have no obligation to Reseller to defend or satisfy any Claims made against Reseller that arise from the use, marketing, licensing or disposition of the Products by Reseller that is not expressly authorized by this Agreement. In the event any such Claim is brought or threatened, Cipherloc may, at its sole option and expense: (i) procure for Reseller the right to continue use of the Product or infringing part thereof; and/or (ii) modify or amend the Product or infringing part, or replace the Product or infringing part with other software or product having substantially the same or better capabilities. If neither of the foregoing is commercially practicable, Cipherloc may terminate this Agreement with respect to the infringing part of the Product, whereupon Cipherloc shall refund a pro rata portion of the fees (based on a useful life equal to three (3) years) paid by Reseller for the infringing Product. If Cipherloc supplies a non-infringing update or version of the Product, Reseller shall promptly supply the same to its End Users and install the same at its End User locations. If, in its judgment, Cipherloc deems that, due to the Claim or for any other reason, it is not in Cipherloc’s interest to continue distributing the Products, Cipherloc, without breaching this Agreement, may terminate the distribution of any or all of the Products. THE REMEDIES SET FORTH IN THIS SECTION 8.3 SHALL BE Reseller’s SOLE AND EXCLUSIVE REMEDIES IN THE EVENT OF AN INFRINGEMENT CLAIM RELATING TO THE PRODUCTS.

 

8.4 Indemnification Conditions . The indemnification obligation in Sections 8.3 and 8.4 shall be effective only if (1) the party seeking indemnification (the “Indemnified Party”) gives prompt notice of the Claim and permits, and gives the party providing the indemnification (the “Indemnifying Party”) the sole authority, to control the defense and settlement, if any, and (2) Indemnified Party cooperates in the defense of the Claim by giving such assistance and information as the Indemnifying Party may require to settle or oppose such Claims. The Indemnifying Party shall have the exclusive right to defend any such Claims and make settlements thereof at its own discretion, and the Indemnified Party may not settle or compromise such Claims, action or allegation, except with the prior written consent of Indemnifying Party.

 

9. REPRESENTATIONS AND WARRANTIES OF THE PARTIES

 

9.1 Compliance with Laws . Reseller represents and agrees that it will not conduct business under this Agreement in any jurisdiction without first obtaining all approvals required in such jurisdiction. The appointment of Reseller as a reseller under this Agreement shall not become effective with respect to any jurisdiction unless and until all government or trade association approvals required by the laws of such jurisdictions have been issued, and Reseller shall cease all sales and marketing of the Products in any jurisdiction for which Cipherloc provides written notice that (i) sales of the Products in that jurisdiction are prohibited or restricted under the export control laws or regulations of the United States; or (ii) in Cipherloc’s reasonable opinion that jurisdiction does not provide adequate and effective protection for Cipherloc’s confidential information, trademarks and/or other Intellectual Property Rights. In addition, Reseller agrees not to take any actions to register as a dealer or distributor in a jurisdiction where the effect of such registration would be to either grant Reseller exclusive distribution rights in such jurisdiction with respect to the Products or otherwise substantially impede the ability of Cipherloc or any other business Reseller of Cipherloc to act legally as a dealer or distributor in such jurisdiction. If the laws of a particular jurisdiction effectively prohibit the ability of Cipherloc to have more than one of its business resellers to distribute Products in such jurisdiction, Reseller acknowledges and agrees that the choice of which business reseller to use in such jurisdiction will belong solely to Cipherloc and that Cipherloc may appoint a business reseller to act exclusively on its behalf in such jurisdiction without breaching any provisions of this Agreement.

 

8
 

 

9.2 Defective Materials — Limited Warranty Policy . Cipherloc warrants that the media upon which the Products are delivered by Cipherloc pursuant to this Agreement shall be free from defects in material and workmanship at the time of purchase and that Cipherloc will replace any such media found to be defective, provided such defect is reported to Cipherloc within thirty (30) days of delivery of the Product to Reseller or the End User, as the case may be. At the option of Cipherloc, the defective media (including the original distribution program media) must be returned to Cipherloc in its entirety or destroyed by Reseller. In the case of destruction, Reseller must execute and deliver to Cipherloc a “destruction certificate”, in a form and substance acceptable to Cipherloc, certifying that the defective media has been destroyed. Returned Products will be replaced at no charge, including shipping charges, within ten (10) days of its receipt by Cipherloc. Cipherloc further warrants to Reseller that the Products shall perform substantially in accordance with the product description set forth in the relevant Documentation that accompanies the Products, as it may exist from time to time. Cipherloc does not warrant that the Products shall operate in combination with other software selected by Reseller or End User, or that the Products shall operate uninterrupted or free of errors. If the Products do not perform as warranted, Reseller’s sole and exclusive remedy shall be as follows: Cipherloc shall undertake commercially reasonable efforts to correct the Products, and if after undertaking such commercially reasonable efforts, Cipherloc determines that it is unable to correct the Product, Cipherloc shall refund to Reseller an amount equal to a pro rata portion of the fees paid by Reseller for the non-conforming Product based on a useful life of three (3) years. The limited warranties in this Section 9.2 are made to and for the benefit of Reseller only and are conditioned upon Reseller E’s use of the Products in accordance with the terms of this Agreement, the Documentation and other reasonable instructions provided by Cipherloc. These limited warranties shall not apply to Products to the extent that a Product error occurs because of and would not have occurred but for: (i) modifications made to the Product (other than those provided by Cipherloc under this Agreement or through product support); (ii) the End User’s failure to implement bug fixes, error corrections and enhancements as required by Cipherloc; (iii) use of the Products in connection with any computer equipment or devices not specified in the Documentation or otherwise not approved in writing by Cipherloc; or (iv) installation or use of the Products contrary to the specifications and directions contained in the Documentation or other reasonable instructions of Cipherloc. No employee, agent, representative or affiliate of Cipherloc has authority to bind Cipherloc to any oral representations or warranty concerning the Products. Any written representation or warranty not expressly contained in this Agreement is not authorized and is unenforceable. No amendment to this Agreement altering or adding a representation or warranty shall be effective unless set forth in a writing executed by an authorized representative of Cipherloc.

 

9.3 Disclaimer of Warranty . EXCEPT FOR THE LIMITED WARRANTIES PROVIDED ABOVE IN SECTION 9.2, THE PRODUCTS ARE PROVIDED “AS-IS” AND CIPHERLOC MAKES NO OTHER WARRANTIES, WHETHER EXPRESS, IMPLIED, OR STATUTORY, REGARDING OR RELATING TO THE PRODUCTS OR ANY MATERIALS OR SERVICES FURNISHED OR PROVIDED TO RESELLER UNDER THIS AGREEMENT. TO THE FULLEST EXTENT ALLOWED BY LAW, CIPHERLOC SPECIFICALLY DISCLAIMS ALL IMPLIED WARRANTIES OF TITLE, MERCHANTABILITY, NON-INFRINGEMENT, AND FITNESS FOR A PARTICULAR PURPOSE (EVEN IF CIPHERLOC HAS BEEN INFORMED OF SUCH PURPOSE).

 

9
 

 

10. LIMITATIONS OF LIABILITY

 

10.1 Limitation of Liability . EXCEPT FOR EACH PARTY’S OBLIGATIONS UNDER SECTION 11 (CONFIDENTIAL INFORMATION), IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES (INCLUDING DAMAGES FOR LOSS OF BUSINESS PROFITS, BUSINESS INTERRUPTION, LOSS OF BUSINESS INFORMATION OR OTHER PECUNIARY LOSS) WHETHER IN CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, WHETHER FORESEEABLE OR NOT AND WHETHER OR NOT THE OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES; PROVIDED, HOWEVER, THAT THE FOREGOING SHALL NOT BE CONSTRUED TO LIMIT LICENSEE’S LIABILITY FOR PAYMENT FOR ALL COPIES OF THE LICENSED SOFTWARE MADE BY OR ON BEHALF OF LICENSEE OR FOR INFRINGEMENT OR MISUSE OF CIPHERLOC’S PROPRIETARY RIGHTS OR CONFIDENTIAL INFORMATION.

 

IN NO EVENT SHALL CIPHERLOC’S TOTAL LIABILITY (WHETHER IN CONTRACT, TORT, OR UNDER ANY OTHER FORM OF LIABILITY) UNDER THIS AGREEMENT EXCEED THE AGGREGATE AMOUNT PAID OR DUE FOR PAYMENT BY RESELLER FOR THE SPECIFIC PRODUCTS WHICH ARE THE SUBJECT OF THE CLAIM.

 

TO THE EXTENT THAT SOME JURISDICTIONS DO NOT ALLOW THE EXCLUSION OR LIMITATION OF CONSEQUENTIAL OR INCIDENTAL DAMAGES, THE ABOVE LIMITATION MAY NOT APPLY AND IN SUCH JURISDICTIONS THE LIABILITY OF EITHER PARTY SHALL BE LIMITED TO THE MAXIMUM EXTENT PERMITTED BY LAW. THE PARTIES AGREE THAT THE ABOVE WARRANTIES AND LIMITATIONS OF LIABILITY REFLECT THE ALLOCATION OF RISK AMONG THE PARTIES AND THE PRICE OF THE PRODUCT.

 

10.2 Time Period . No action, regardless of form, may be brought against a party by the other party more than two (2) years after the claim has arisen.

 

10.3 Exclusive Remedies . THE REMEDIES PROVIDED IN THIS AGREEMENT ARE THE SOLE AND EXCLUSIVE REMEDIES OF THE PARTIES AND SHALL APPLY NOTWITHSTANDING FAILURE OF THEIR ESSENTIAL PURPOSE.

 

11. CONFIDENTIAL INFORMATION

 

11.1 Non-Disclosure . Each party acknowledges that it may receive Confidential Information from the other party. “ Confidential Information ” means any information, technical data or know-how, including, without limitation, that which relates to computer software programs or documentation, specifications, source code, object code, research, inventions, processes, designs, drawings, engineering, products, services, customers, sales leads, markets or finances of the disclosing party which is identified as confidential at the time of disclosure. Confidential Information shall be treated as confidential if it is disclosed in documentary or tangible form marked “Confidential” or, in the case of disclosures made orally or by visual inspection, identified as “Confidential” at the time of disclosure. Each party agrees that all Confidential Information of the other party shall be held in strict confidence and shall not be disclosed or used without the express prior written consent of the other party. The receiving party shall exercise at least the same degree of care, but not less than reasonable care, to safeguard the Confidential Information of the disclosing party as the receiving party would exercise to safeguard similar information of its own. The receiving party shall not disclose the disclosing party’s Confidential Information, or any part or parts thereof, to any of its employees, agents, or contractors except on a “need to know” basis. Confidential Information shall not include any information (i) already in the possession of the receiving party; (ii) received without an obligation of confidentiality; (iii) independently developed by the receiving party without use of the disclosing party’s Confidential Information; (iv) in the public domain; (v) authorized for disclosure by the disclosing party; (vi) disclosed by order of law or court order; or (vii) released without restriction by the disclosing party.

 

10
 

 

11.2 Protected Period. The obligations set forth in this Section 11 shall continue for a period of two (2) years after termination of this Agreement.

 

12. TERM AND TERMINATION

 

12.1 Term . The term of this Agreement (“ Term ”) shall commence on the Effective Date for an initial period of five (5) years unless otherwise earlier terminated by either party as provided herein. Thereafter, the Term shall automatically renew and be extended for successive five (5) year periods unless either party shall have provided the other with written notice, at least sixty (60) days before the relevant anniversary of the Effective Date, of its election not to have the Term renew past such anniversary date.

 

12.2 Termination by Cipherloc . Cipherloc may terminate this Agreement immediately upon written notice to Reseller if Reseller (a) breaches or fails to comply with any of the terms or conditions of this Agreement, (b) fails to maintain a satisfactory credit rating or financial condition or if Cipherloc reasonably concludes that, for any reason, Reseller is or will become unable to discharge its obligations hereunder, or (c) breaches or fails to comply with any of the terms or conditions of Cipherloc’s Certification Process.

 

12.3 Termination by Reseller . Without prejudice to rights set forth in Section 12.2, Reseller may terminate this Agreement upon 90 written notice to Cipherloc in the event of (a) liquidation or insolvency of the Cipherloc, (b) the appointment of a receiver or similar officer for Cipherloc, (c) assignment by Cipherloc for the benefit of creditors, or (d) the filing of a petition in bankruptcy by or against Cipherloc or any similar petition under the insolvency laws of any jurisdiction, which in the case of a filing against Cipherloc is not dismissed in sixty (60) days.

 

12.4 Liability . Termination of this Agreement pursuant to Section 12.2 or Section 12.3 shall not release the other party from any liability for any breach of this Agreement.

 

12.5 Rights and Duties on Termination or Expiration .

 

12.5.1 Payment of Amounts Due . Termination or expiration of this Agreement shall not relieve either party of the obligation to pay any amount due to the other that accrued prior to the time of the termination or expiration. Further, Reseller agrees to pay Cipherloc, as they come due, all support fees and other service or support revenues relating to Products that are owed to Cipherloc, including those accrued or received by Reseller after termination or expiration.

 

12.5.2 Termination of Licenses . Upon termination or expiration of this Agreement, the distribution license and all related licenses and rights granted to Reseller hereunder, including, but not limited to, the Demonstration Software license and limited trademark license shall terminate immediately and Reseller shall make no further use of all or any part of the Products, Demonstration Software, Cipherloc Trademarks, or Cipherloc Confidential Information. Reseller shall (a) immediately cease any public statements or representations that it is an authorized Cipherloc Reseller or that it is in any way associated with Cipherloc and (b) immediately return to Cipherloc all Demonstration Software and Cipherloc Confidential Information.

 

11
 

 

12.5.3 Survival . All obligations of the parties which expressly or by their nature survive the expiration or termination of this Agreement, including the parties’ limitation of liability, indemnity and confidentiality obligations shall continue in full force and effect until they are satisfied in full or by their nature expire.

 

12.5.4 Continued Use of Licensed Software . Upon termination or expiration of this Agreement, any End User who previously purchased the Product from RESELLER shall have the continuing right to use the Product in accordance with the terms and conditions of the applicable EULAs, which shall survive termination or expiration of this Agreement. Cipherloc shall continue to fulfill orders for the Products to End Users submitted prior to the date of termination, provided that Reseller pre-pays in full such orders.

 

13. GENERAL PROVISIONS

 

13.1 No Joint Venture. It is expressly understood that the parties are acting as independent contractors hereunder and not as an agent or representative of the other. This Agreement does not constitute a joint venture. Neither party shall enter into any contract or commitment on behalf of the other.

 

13.2 Force Majeure . Neither party shall be held responsible for any reasonable delay or failure in performance hereunder (except with respect to the obligation to make payments hereunder) caused by fires, strikes, embargoes, acts of nature, or other causes beyond their reasonable control.

 

13.3 Notice . All notices or other communications required or permitted hereunder shall be in writing and shall be deemed to have been duly given either when delivered personally, by confirmed facsimile transmission, or five (5) days after being placed, properly addressed to the addresses set forth above with first class, postage prepaid, return receipt requested, in the United States mail, or sent by registered airmail, properly addressed to the addresses set forth above, postage prepaid and return receipt requested. Notice of change of address shall be given by written notice in the manner detailed in this Section.

 

13.4 Entire Agreement . This Agreement and the Schedules and Exhibits hereto constitute the entire understanding between the parties hereto with respect to the subject matter hereof and supersede any and all prior agreements and understandings between the parties hereto with respect to the subject matter hereof, including, without limitation, any warranties, representations, or agreements between Reseller and Cipherloc not set forth in this Agreement.

 

13.5 Modification. This Agreement may be supplemented, amended, or modified only by the mutual agreement of each party and shall only be effective if in a writing signed by each party.

 

13.6 Assignment . This Agreement, the licenses granted, and the parties’ rights and obligations hereunder may not be assigned by either party, including as part of a Change of Control transaction, except with the express written consent of the other party, which consent shall not be unreasonably withheld. Any purported assignment not in compliance with the foregoing shall be null and void and of no effect; provided, however, that Cipherloc may assign this Agreement without Reseller’s prior written approval when in connection with a Change of Control transaction. Notwithstanding the foregoing, this Agreement shall be binding upon and inure to the benefit of the parties and its respective heirs, personal representatives, successors and assigns.

 

12
 

 

13.7 Severability. This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the validity or enforceability of this Agreement or of any other term or provision hereof. Any headings contained herein are for convenience only and shall not affect the construction hereof. This Agreement may be executed in multiple counterparts, each of which shall be deemed to be an original, and all such counterparts shall constitute one instrument. If any provision or part thereof of this Agreement is stricken in accordance with the provisions of this Section, then this stricken provision shall be replaced, to the extent possible, with a legal, enforceable, and valid provision that is as similar in tenor to the stricken provision as is legally possible.

 

13.8 Governing Law . This Agreement shall be governed by and construed in accordance with the laws of the State of Texas without regard to principles of conflicts of law.

 

13.9 Costs and Attorney Fees. The prevailing party shall be entitled to recover, in addition to any other remedy, its reasonable attorney fees, court costs, costs of investigation, expert fees and other related expenses incurred in connection with any enforcement of rights under this Agreement.

 

13.10 Waiver . The failure or delay of any party to exercise any right or option arising out of a breach of this Agreement shall not be deemed a waiver of any right or option with respect to any subsequent or different breach, or the continuance of any existing breach, after demand for strict performance.

 

13.11 Representation on Authority of Parties/Signatories. Each person signing this Agreement represents and warrants that he or she is duly authorized and has legal capacity to execute and deliver this Agreement. Each party represents and warrants to the other that the execution and delivery of the Agreement and the performance of such party’s obligations hereunder have been duly authorized and that the Agreement is a valid and legal agreement binding on such party and enforceable in accordance with its terms.

 

13.12 Injunctive Relief . The parties recognize that a remedy at law for a breach of the provisions of this Agreement relating to Confidential Information, or use of Cipherlocs’ trademarks, copyrights, and other Intellectual Property Rights, will not be adequate for the parties’ protection, and accordingly the non-breaching party shall have the right to obtain, in addition to any other relief and remedies available to it, injunctive relief to enforce the provisions of this Agreement.

 

13.13 Ambiguities. Each party and its counsel have had the opportunity to participate fully in the review and revision of this Agreement. Any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not apply in interpreting this Agreement. The language in this Agreement shall be interpreted as to its fair meaning and not strictly for or against any party.

 

13.14 Mutual Non-solicitation of Employees . During the term of this Agreement and for a period of one (1) year following termination of this Agreement, neither Cipherloc nor Reseller (nor any of their respective subsidiaries), without the prior written consent of the other party, shall directly or indirectly solicit for employment or employ any employee of the other party with whom it has worked during the performance of this Agreement. However, this restriction shall not prohibit a party from carrying on and hiring employees of the other party who have responded to general industry solicitations in trade journals, through head-hunters and the like .

 

IN WITNESS WHEREOF, the parties have executed and delivered this Agreement as of the date first written above.

 

Cipherloc Corporation   Quality Health Care International LLC
         
By /s/ Michael De La Garza   By /s/ Roberta Kale
  Michael De La Garza     Roberta Kale
  President/CEO     President/CEO

 

13
 

 

Schedule A

 

Products:

 

All products listed on the Price List

 

Territory:

 

United States and Territories

 

Other countries made be added from time to time as mutually agreed by the parties

 

Customers:

 

All licensed Healthcare Providers in the United States and Territories which includes hospitals, ambulatory services companies, public and private education entities providing health education and training, healthcare insurance companies, government healthcare provides such as the Center for Medicare Administration (CMA), Veteran’s Administration and Indian Health Services, home health providers, pharmaceutical companies and distributors, and durable medical providers.

 

Demonstration Software:

 

During the Term, Cipherloc may develop and provide Reseller with Demonstration Software. Subject to the terms and conditions of this Agreement and the applicable EULAs, during the Term Cipherloc grants Reseller a non-exclusive, non-transferable right and license to use any such Demonstration Software with potential Reseller customers in the Territory for evaluation, demonstration, marketing, promotional activities, and compatibility testing and analysis.

 

Additional Cipherloc Termination Right for Failing to Meet Annual Revenue Goal

 

Should Reseller fail to purchase a minimum of $1,000,000 of Cipherloc Products on an annual basis measured initially from the twenty four month period from the Effective Date, Cipherloc shall have the right to terminate this Agreement effectively immediately upon written notice to Reseller. For avoidance of doubt, the parties agree that Reseller’s failure to meet this minimum annual revenue goal is not a breach of the Agreement.

 

RESELLER’S Discount for Products:

 

  Software:

 

  Fifteen percent (15%) discount from the Cipherloc Price List for any new perpetual software licenses or the first year of a subscription software license.
     
  Twenty-Five (25%) discount from the Cipherloc Price List for any new perpetual software licenses or the first year of a subscription software license for approved Registered Opportunities.

 

  Maintenance and support services, Cipherloc professional services and hardware purchased in conjunction with Software listed above:

 

  Five percent (5%) discount from the Cipherloc Price List for any new perpetual software licenses or the first year of a subscription software license.

 

  Renewal of software subscription licenses or support and maintenance agreements sold beyond the first year of the sale of a perpetual software license:

 

  Five percent (5%) discount from the Cipherloc Price List for any new perpetual software licenses or the first year of a subscription software license.

 

RESELLER’S Discount for Products to End Users on Pass-Through Sales:

 

Five (5%) discount from the Cipherloc Price List.

 

“Pass-Through Sales” is defined as a sale whereby Reseller is acting as a fulfillment Reseller for the End User at the request of the End User or Cipherloc and is not significantly involved in the selling process.

 

14
 

 

Schedule B

 

Training

 

Cipherloc will schedule training for Reseller within ninety (90) days of the Effective Date and, during this time period, Reseller agrees to have two sales personnel and two technical personnel complete a total of 4 hours of web-based training on Cipherloc Products.

 

15
 

 

Exhibit A

 

PROMISSORY NOTE

 

$416,000 May 30, 2019

 

FOR VALUE RECEIVED, Quality Health Care International, LLC, a Nevada limited liability company located at 192 Hanna Court, Mesquite, NV 89027 (“Debtor”) promises to pay to the order of Cipherloc Corporation a Texas corporation, located at 825 Main Street, Suite 100, Buda, TX 78610 (Creditor), or such other place and person as Creditor may from time to time designate in writing, in lawful money of the United States of America, the principal sum of Four Hundred Sixteen Thousand dollars ($416,000.00) together with interest commencing the e first year anniversary of this Note on the unpaid principal balance at the rate of four percent (4%) per year on or before May 29, 2021.

 

Payments. Payments shall be made by Debtor pursuant to a certain Reseller Agreement entered between the Debtor and Creditor on May 30, 2019. In said Agreement the Debtor is the Reseller and the Creditor is Cipherloc Corporation

 

Debtor will pay to Creditor all outstanding indebtedness evidenced by this Note (including any unpaid principal and any accrued and unpaid interest) on or before May 29, 2021 on or before the first of the following to occur:

 

(a) any sale, assignment or transfer of all or any substantial portion of the assets of Debtor or any of its affiliates;

 

(b) any sale, assignment or transfer of a majority of the issued and outstanding shares of any class of stock or other equity interests of Debtor or any of its affiliates;

 

(c) any merger, consolidation, recapitalization or reorganization of Debtor or any of its affiliates;

 

(d) receipt by Debtor or any of its affiliates of One Million Dollars ($1,000,000.00) or more in connection with any financing (debt or equity), strategic alliance, joint venture, licensing or other transaction or series of related transactions; or

 

(e) Creditor’s demand for payment given at any time on or after May 29, 2021.

 

Debtor shall have the right to prepay the principal balance due under this Note in whole or in part (together with all accrued and unpaid interest) at any time without penalty.

 

Business/Commercial Purpose. Debtor hereby represents and warrants to Creditor that this Note arises exclusively for business or commercial purposes, and that this Note does not arise from any personal, family or household purposes.

 

 
 

 

Governing Law; Jurisdiction and Venue. This Note shall be governed by and construed and enforced in accordance with the laws of the State of Arizona, without regard to its conflicts of law principles to the contrary. Debtor consents to the jurisdiction and venue in the state and federal courts situated in Maricopa County, Arizona for any action relating to this Note.

 

Miscellaneous. Debtor and all endorsers, sureties, accommodation parties, and all persons liable or to become liable on this Note, and each of them, hereby severally waive diligence, demand, presentment for payment, notice of nonpayment, notice of dishonor, protest and notice of protest, and specifically consent to and waive notice of any renewals or extensions of this Note or any part of the whole of the debt evidenced by this Note, whether made to or in favor of Debtor or any other person or persons, and further agree that any such action by Creditor shall not affect the liability of Debtor or any persons liable or to become liable on this Note. Such consent shall not alter or diminish the liability of any person or the enforceability of this Note. Each and every party signing or endorsing this Note binds itself as a principal and not as a surety. No waiver or modification of this Note shall be effective unless it is express, in writing and signed by the party against whom enforcement of the waiver or modification is sought. Any failure of the parties to comply with any obligation, agreement or condition contained in this Note may be expressly waived in writing by the other party, but such waiver or failure to insist upon strict compliance shall not operate as a waiver of, or estoppel with respect to, any subsequent or other failure. The terms and conditions of this Note shall inure to the benefit of and be binding upon the respective successors, assigns, heir and legal representatives of the parties.

 

DATED as of the day and year first above written.

 

  Debtor:
   
  Quality Health Care International, LLC
   
  By: /s/ Roberta Kale
    Roberta Kale, President/CEO

 

- 2  -
 

 

 

 

 

Exhibit 31.1

 

Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and pursuant to Rule 13a-14(a) and Rule 15d-14 under the Securities Exchange Act of 1934 for the period ending March 31, 2019.

 

I, Michael De La Garza, certify that:

 

1 I have reviewed this Quarterly Report on Form 10-Q of Cipherloc Corporation;
   
2 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3 Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4 The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations: and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Registrant Cipherloc Corporation
     
Date: June 5, 2019 By: /s/ Michael De La Garza
    Michael De La Garza
    Chariman, Chief Executive Officer (Principal Executive Officer), President

 

     

 

 

 

Exhibit 31.2

 

Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and pursuant to Rule 13a-14(a) and Rule 15d-14 under the Securities Exchange Act of 1934 for the period ending March 31, 2019

 

I, Michael De La Garza, certify that:

 

1 I have reviewed this Quarterly Report on Form 10-Q of Cipherloc Corporation;
   
2 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations: and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Registrant Cipherloc Corporation
     
Date: June 5, 2019 By:

/s/ Michael De La Garza

    Michael De La Garza
    Acting Chief Financial Officer (Principal Financial Officer)

 

     

 

 

 

Exhibit 32.1

 

CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

 

In connection with the Quarterly Report of Cipherloc Corporation (the “Company”) on Form 10-Q for the period ending March 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael De La Garza, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Registrant Cipherloc Corporation
   
Date: June 5, 2019 By: /s/ Michael De La Garza
    Michael De La Garza
    Chairman, Chief Executive Officer (Principal Executive Officer), President

 

     

 

 

 

Exhibit 32.2

 

CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

 

In connection with the Quarterly Report of Cipherloc Corporation (the ‘Company’) on Form 10-Q for the period ending March 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the ‘Report’), I, Michael De La Garza, Acting Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(3)   The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
     
(4)   The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Registrant Cipherloc Corporation
     
Date: June 5, 2019 By: /s/ Michael De La Garza
    Michael De La Garza
    Acting Chief Financial Officer (Principal Financial Officer)